Tags

Type your tag names separated by a space and hit enter

Pharmacoeconomic Review Report: Buprenorphine extended-release injection (Sublocade): (Indivior Canada, Ltd.): Indication: For the management of moderate-to-severe opioid use disorder in adult patients who have been inducted and clinically stabilized on a transmucosal buprenorphine-containing product

Abstract
Buprenorphine extended-release injection (BUP-ER; Sublocade) is indicated for the management of moderate-to-severe opioid use disorder (OUD) in adult patients who have been inducted and clinically stabilized on the equivalent of 8 mg per day to 24 mg per day of transmucosal buprenorphine-containing product in combination with counselling and psychosocial support. BUP-ER is available as 100 mg and 300 mg single-use pre-filled syringe at a submitted price of $550 for either dose. The recommended dosage schedule is 300 mg injection per month for the first two months followed by maintenance on monthly 100 mg injections. The monthly maintenance dose may be increased to 300 mg if the patient does not demonstrate satisfactory response and can tolerate the 100 mg dose, although the 300 mg maintenance dose in clinical trials did not provide additional efficacy compared with the 100 mg dose and was associated with a higher incidence of adverse events and study discontinuations. The manufacturer submitted a cost-utility analysis comparing 100 mg and 300 mg BUP-ER (i.e., 300 mg BUP-ER every four weeks for two doses followed by 100 mg or 300 mg BUP-ER monthly) to oral methadone and generic buprenorphine/naloxone in adults with moderate-to-severe OUD.

Publisher

Canadian Agency for Drugs and Technologies in Health
Ottawa (ON)

Language

eng

PubMed ID

31532597

Citation

Pharmacoeconomic Review Report: Buprenorphine extended-release injection (Sublocade): (Indivior Canada, Ltd.): Indication: For the management of moderate-to-severe opioid use disorder in adult patients who have been inducted and clinically stabilized on a transmucosal buprenorphine-containing product. Canadian Agency for Drugs and Technologies in Health, 2019, Ottawa (ON).
Pharmacoeconomic Review Report: Buprenorphine extended-release injection (Sublocade): (Indivior Canada, Ltd.): Indication: For the management of moderate-to-severe opioid use disorder in adult patients who have been inducted and clinically stabilized on a transmucosal buprenorphine-containing product. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019.
(2019). In Pharmacoeconomic Review Report: Buprenorphine extended-release injection (Sublocade): (Indivior Canada, Ltd.): Indication: For the management of moderate-to-severe opioid use disorder in adult patients who have been inducted and clinically stabilized on a transmucosal buprenorphine-containing product. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health;
Pharmacoeconomic Review Report: Buprenorphine extended-release injection (Sublocade): (Indivior Canada, Ltd.): Indication: For the management of moderate-to-severe opioid use disorder in adult patients who have been inducted and clinically stabilized on a transmucosal buprenorphine-containing product. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019.
* Article titles in AMA citation format should be in sentence-case
TY - BOOK T1 - Pharmacoeconomic Review Report: Buprenorphine extended-release injection (Sublocade): (Indivior Canada, Ltd.): Indication: For the management of moderate-to-severe opioid use disorder in adult patients who have been inducted and clinically stabilized on a transmucosal buprenorphine-containing product Y1 - 2019/07// PY - 2019/9/19/pubmed PY - 2019/9/19/medline PY - 2019/9/19/entrez N2 - Buprenorphine extended-release injection (BUP-ER; Sublocade) is indicated for the management of moderate-to-severe opioid use disorder (OUD) in adult patients who have been inducted and clinically stabilized on the equivalent of 8 mg per day to 24 mg per day of transmucosal buprenorphine-containing product in combination with counselling and psychosocial support. BUP-ER is available as 100 mg and 300 mg single-use pre-filled syringe at a submitted price of $550 for either dose. The recommended dosage schedule is 300 mg injection per month for the first two months followed by maintenance on monthly 100 mg injections. The monthly maintenance dose may be increased to 300 mg if the patient does not demonstrate satisfactory response and can tolerate the 100 mg dose, although the 300 mg maintenance dose in clinical trials did not provide additional efficacy compared with the 100 mg dose and was associated with a higher incidence of adverse events and study discontinuations. The manufacturer submitted a cost-utility analysis comparing 100 mg and 300 mg BUP-ER (i.e., 300 mg BUP-ER every four weeks for two doses followed by 100 mg or 300 mg BUP-ER monthly) to oral methadone and generic buprenorphine/naloxone in adults with moderate-to-severe OUD. PB - Canadian Agency for Drugs and Technologies in Health CY - Ottawa (ON) UR - https://www.unboundmedicine.com/medline/citation/31532597/Pharmacoeconomic_Review_Report:_Buprenorphine_extended-release_injection_(Sublocade):_(Indivior_Canada,_Ltd.):_Indication:_For_the_management_of_moderate-to-severe_opioid_use_disorder_in_adult_patients_who_have_been_inducted_and_clinically_stabilized_on_a_transmucosal_buprenorphine-containing_product L2 - https://www.ncbi.nlm.nih.gov/books/NBK546358 DB - PRIME DP - Unbound Medicine ER -
Unbound Prime app for iOS iPhone iPadUnbound PubMed app for AndroidAlso Available:
Unbound MEDLINE
Unbound PubMed app for Windows